The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care
Open accessAbstract
INTRODUCTION: The eighth edition of the American Joint Committee on Cancer (AJCC) melanoma staging system was implemented in the United States on 1 January 2018. Areas covered: This article provides an overview of important changes in the eighth edition AJCC staging system from the seventh edition based on analyses of a large international melanoma database. The clinical implications of these changes for melanoma treatment are also discussed. Expert commentary: A standardized and contemporary cancer staging system that facilitates accurate risk stratification is essential to guide patient treatment. The eighth edition of the AJCC staging system is currently the most widely accepted approach to melanoma staging and classification at initial diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., et al. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21409 · Cited by 2,283
Self-citationAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Nieweg, O. E., Roses, D. F., Hoekstra, H. J., Karakousis, C. P., Puleo, C. A., Coventry, B. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310460 · Cited by 1,484
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Self-citationAmerican Joint Committee on Cancer (2010) · Springer eBooks · doi:10.1007/978-0-387-88441-7 · Cited by 1,328
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Goldberg, S. B., Gettinger, S. N., Mahajan, A., Chiang, A. C., Herbst, R. S., Sznol, M., Tsiouris, A. J., Cohen, J., Vortmeyer, A., Jilaveanu, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30053-5 · Cited by 993
Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70431-x · Cited by 918
Leiter, U., Stadler, R., Mauch, C., Hohenberger, W., Brockmeyer, N., Berking, C., Sunderkötter, C., Kaatz, M., Schulte, K.-W., Lehmann, P., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00141-8 · Cited by 707
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589
Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth, A., Wanek, L. A., & Morton, D. L. (1995) · PubMed · Cited by 569
Prognostic factors for survival in melanoma patients with brain metastases
Davies, M. A., Liu, P., McIntyre, S., Kim, K. B., Papadopoulos, N., Hwu, W., Hwu, P., & Bedikian, A. (2011) · Cancer · doi:10.1002/cncr.25634 · Cited by 548
Tumor Thickness, Level of Invasion and Node Dissection in Stage I Cutaneous Melanoma
BRESLOW, A. (1975) · Annals of Surgery · doi:10.1097/00000658-197511000-00007 · Cited by 527
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Ding, S., Byrd, D. R., Cascinelli, N., Cochran, A. J., Coit, D. G., Eggermont, A. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1627 · Cited by 410
Self-citationManola, J., Atkins, M., Ibrahim, J., & Kirkwood, J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3782 · Cited by 374
Thompson, J. F., Soong, S.-J., Balch, C. M., Gershenwald, J. E., Ding, S., Coit, D. G., Flaherty, K. T., Gimotty, P. A., Johnson, T., Johnson, M. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.5812 · Cited by 363
Self-citationLong, G. V., Grob, J.-J., Nathan, P., Ribas, A., Robert, C., Schadendorf, D., Lane, S. R., Mak, C., Legenne, P., Flaherty, K. T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30578-2 · Cited by 315
Amaria, R. N., Prieto, P. A., Tetzlaff, M. T., Reuben, A., Andrews, M. C., Ross, M. I., Glitza, I. C., Cormier, J., Hwu, W.-J., Tawbi, H. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30015-9 · Cited by 299
Self-citationLactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R. R. H., Hospers, G. A. P., van den Eertwegh, A. J. M., Kapiteijn, E. W., de Groot, J. W. B., Soetekouw, P., Jansen, R. L., et al. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1528-9 · Cited by 298
Long, G. V., Weber, J. S., Infante, J. R., Kim, K. B., Daud, A., Gonzalez, R., Sosman, J. A., Hamid, O., Schuchter, L., Cebon, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.9345 · Cited by 285
Wong, S. L., Faries, M. B., Kennedy, E. B., Agarwala, S. S., Akhurst, T. J., Ariyan, C., Balch, C. M., Berman, B. S., Cochran, A., Delman, K. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7724 · Cited by 284
van Akkooi, A. C. J., Nowecki, Z. I., Voit, C., Schäfer-Hesterberg, G., Michej, W., de Wilt, J. H. W., Rutkowski, P., Verhoef, C., & Eggermont, A. M. M. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31818fefe0 · Cited by 253
Identification of High-Risk Patients Among Those Diagnosed With Thin Cutaneous Melanomas
Gimotty, P. A., Elder, D. E., Fraker, D. L., Botbyl, J., Sellers, K., Elenitsas, R., Ming, M. E., Schuchter, L., Spitz, F. R., Czerniecki, B. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1463 · Cited by 208
Green, A. C., Baade, P., Coory, M., Aitken, J. F., & Smithers, M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8561 · Cited by 206
ARMSTRONG, B. K. (1984) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a072002 · Cited by 194
Tripp, M. K., Watson, M., Balk, S. J., Swetter, S. M., & Gershenwald, J. E. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21352 · Cited by 184
Self-citationNagore, E., Oliver, V., Estrada, R. B., Moreno-Picot, S., Insa, A., & Fortea, J. M. (2005) · Melanoma Research · doi:10.1097/00008390-200506000-00005 · Cited by 143
Role of Sentinel Lymph Node Biopsy in Patients with Thin Melanoma
Andtbacka, R. H. I., & Gershenwald, J. E. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0023 · Cited by 126
Self-citationNosrati, A., Tsai, K. K., Goldinger, S. M., Tumeh, P. C., Grimes, B. A., Loo, K. L., Algazi, A. P., Nguyen‐Kim, T. D. L., Levesque, M. P., Dummer, R., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.70 · Cited by 126
(Neo)adjuvant systemic therapy for melanoma
van Zeijl, M. C. T., van den Eertwegh, A. J. M., Haanen, J. B. A. G., & Wouters, M. W. J. M. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.001 · Cited by 65
Sobin, L. H., Brierley, J. D., Gospodarowicz, M. K., O’Sullivan, B., & Wittekind, C. (2015) · Wiley eBooks · doi:10.1002/9781119013143.ch4 · Cited by 60
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies
Keung, E. Z.-Y., Ukponmwan, E. U., Cogdill, A. P., & Wargo, J. A. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6379-8 · Cited by 58
Self-citationEggermont, A. M. M., & Dummer, R. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.014 · Cited by 57
Sentinel Lymph Node Biopsy in Thin Cutaneous Melanoma: A Systematic Review and Meta-Analysis
Cordeiro, E., Gervais, M., Shah, P., Hong, N. L., & Wright, F. C. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5137-z · Cited by 51
Menzies, A. M., Wilmott, J. S., Drummond, M., Lo, S., Lyle, M. K., Chan, M. M. K., Thompson, J. F., Guminski, A. D., Carlino, M. S., Scolyer, R. A., et al. (2015) · Cancer · doi:10.1002/cncr.29586 · Cited by 50
Larkin, J., Chiarion‐Sileni, V., González, R., Grob, J., Cowey, C. L., Lao, C. D., Wagstaff, J., Hogg, D., Hill, A., Carlino, M. S., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31822-6 · Cited by 36
Neoadjuvant therapy in melanoma: the next step?
Ascierto, P. A., & Eggermont, A. M. M. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30016-0 · Cited by 24
How to use neoadjuvant medical treatment to maximize surgery in melanoma
Amaral, T. M. S., Tampouri, I., & Garbe, C. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1421460 · Cited by 10
Cited by
Epidemiology of brain metastases and leptomeningeal disease
Lamba, N., Wen, P. Y., & Aizer, A. A. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab101 · Cited by 406
The multiple roles of LDH in cancer
Claps, G., Faouzi, S., Quidville, V., Chehade, F., Shen, S., Vagner, S., & Robert, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00686-2 · Cited by 351
Szadai, L., Velasquez, E., Szeitz, B., Almeida, N. P. D., Domont, G., Betancourt, L. H., Gil, J., Marko-Varga, M., Oskolas, H., Jánosi, Á. J., et al. (2021) · Cancers · doi:10.3390/cancers13236105 · Cited by 18
Metadata
- Authors
- Keung, E. Z., & Gershenwald, J. E.
- Venue
- Expert Review of Anticancer Therapy
- Publisher
- Informa UK Limited
- Published
- 2018-07-18
- Volume
- 18
- Issue
- 8
- Pages
- 775-784
- ISSN
- 1473-7140 (ISSN-L)
- 1744-8328
- OpenAlex
- W2808814350
- Cited by
- 593
- References
- 53
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.